JHOME

Wuhan Jinghong Technology Co., Ltd., formerly known as Wuhan Jinghong Wanfangtang Pharmaceutical Technology Co., Ltd., was established on April 19, 2005. The legal representative is Wang Jianbin, who has served as chairman of the board since December 2012. The company's name was officially changed to Wuhan Jinghong Technology Co., Ltd. on September 24, 2019.

The company's primary business involves the research and development, production, and sales of in-vitro diagnostic (IVD) reagents and instruments, as well as medical imaging equipment. Its product and service scope also extends to biotechnology, pharmaceuticals, health products, and cosmetics. The business operates in the medical device and pharmaceutical market, serving clients that require clinical diagnostic and analysis equipment. The company's revenue streams include the sale of Class I, II, and III medical devices, such as clinical laboratory analysis instruments, medical electronic instruments, and medical X-ray equipment. Additionally, it engages in the import and export of goods and technologies.

A notable milestone includes securing the exclusive agency right in China for the DIAMOND-5A digital medical X-ray photography system from the South Korean company DRGEM in 2016. This move was aimed at expanding its presence in the medical imaging diagnostics field and creating new profit growth opportunities. Keywords: In-vitro diagnostics, IVD, medical imaging, diagnostic reagents, diagnostic instruments, medical X-ray equipment, clinical analysis, biotechnology, pharmaceuticals, medical devices, DRGEM, Wuhan Jinghong, wanfangtang, healthcare technology, clinical laboratory, medical diagnostics, China healthcare